CompletedNCT02431429

Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis

Studying Leishmaniasis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Knight Therapeutics (USA) Inc
Principal Investigator
Jaime Soto, MD
Fundacion Nacional de Dermatologia
Intervention
Miltefosine(drug)
Enrollment
55 target
Eligibility
18-55 years · MALE
Timeline
20152019

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02431429 on ClinicalTrials.gov

Other trials for Leishmaniasis

Additional recruiting or active studies for the same condition.

See all trials for Leishmaniasis

← Back to all trials